REVA Medical specializes in innovative bioresorbable polymer technologies aimed at enhancing vascular therapy. Their flagship product, the MOTIV Bioresorbable Scaffold, is specifically designed for treating below-the-knee peripheral artery disease. This scaffold is constructed from Tyrocore™, a proprietary polymer developed by REVA, and is notable for being the first of its kind to receive CE Mark approval for this application. Additionally, the MOTIV scaffold has been granted FDA Breakthrough Technology Status, underscoring its potential to significantly improve patient outcomes in vascular treatments.

Another key product in REVA's portfolio is the TyroSphere beads, which are bioresorbable embolic microspheres intended for the treatment of hypervascular tumors. These beads are distinguished by their safe degradation and radiopacity, allowing for precise targeting during procedures. Furthermore, the Fantom Encore, a third-generation bioresorbable scaffold made with Tyrocore™, offers advanced features such as radiopacity and the thinnest struts available in the market. Designed to support the artery during the healing process, the Fantom Encore scaffold eventually resorbs, which is intended to enhance long-term patient outcomes and facilitate future treatment options.

United States

REVA Medical, LLC. is a leader in bioresorbable polymer technologies for vascular applications. REVA's lead product, Fantom Encore, is a drug-eluting bioresorbable scaffold for the treatment of coronary artery disease. Fantom Encore is made from Tyrocore, REVA’s proprietary tyrosine derived polymer. Unlike metallic stents, Fantom Encore is designed support the artery through the healing process, and then disappear (or “resorb”) from the body in order to restore natural function to the artery. Learn more at www.revamedical.com.

REVA Medical

Company Details